-
1 month ago | 
jci.org | Parham Ramezani-Rad |Ester Marina-Zárate |Laura Maiorino |Amber Myers
ResearchAIDS/HIVImmunologyOpen Access | 10.1172/JCI185292 J Clin Invest. https://doi.org/10.1172/JCI185292. Copyright © 2025, Ramezani-Rad et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
-
Aug 28, 2024 | 
biorxiv.org | Parisa Yousefpour |Yiming Zhang |Laura Maiorino |Mariane B. Melo
AbstractSaponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out studies in non-human primates (NHPs) comparing the most common clinical adjuvant alum with Saponin/MPLA Nanoparticles (SMNP), a novel ISCOMs-like adjuvant.
-
Aug 18, 2024 | 
nature.com | Konstantine Tchourine |Keene L. Abbott |Florian Gourgue |Brian T. Do |Tenzin Kunchok |Allison Lau | +9 more
AbstractMetastases arise from subsets of cancer cells that disseminate from the primary tumour1,2. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and epigenetic changes that are important for disease initiation and progression, but these factors alone do not predict if and where cancers metastasize3,4. Specific cancer types metastasize to consistent subsets of tissues, suggesting that primary tumour-associated factors influence where cancers can grow.
-
Aug 7, 2024 | 
nature.com | Laura Maiorino |Yiming Zhang |Jack R. Suggs
AbstractSystemically administered cytokines are potent immunotherapeutics but can cause severe dose-limiting toxicities. To overcome this challenge, cytokines have been engineered for intratumoral retention after local delivery. However, despite inducing regression of treated lesions, tumor-localized cytokines often elicit only modest responses at distal untreated tumors.
-
Aug 3, 2024 | 
biorxiv.org | Parham Ramezani-Rad |Ester Marina-Zárate |Laura Maiorino |Amber Myers
AbstractThe induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play an important role as drivers of such responses. Despite advances in vaccine strategies, a safe and effective HIV vaccine remains a significant challenge. The use of an appropriate adjuvant is crucial to the success of HIV vaccines.
-
Jun 27, 2024 | 
biorxiv.org | Maureen Buckley |Mariluz Araínga |Laura Maiorino |Ivan S. Pires
AbstractmRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate enabling positron emission tomography (PET) tracer labeling of LNP/mRNA vaccines for quantitative visualization of vaccine trafficking in live non-human primates (NHPs).
-
Jan 3, 2024 | 
biorxiv.org | Luciano Santollani |Yiming Zhang |Laura Maiorino |Joseph R Palmeri
AbstractCytokine therapies are potent immunotherapy agents but exhibit severe dose-limiting toxicities. One strategy to overcome this involves engineering cytokines for intratumoral retention following local delivery. Here, we develop a localized cytokine therapy that elicits profound anti-tumor immunity by engineered targeting to the ubiquitous leukocyte receptor CD45.
-
Nov 21, 2023 | 
biorxiv.org | Sachin Bhagchandani |Leerang Yang |Laura Maiorino |Elana Ben-Akiva
Abstract"Extended priming" immunization regimens that prolong exposure of the immune system to vaccines during the primary immune response have shown promise in enhancing humoral immune responses to a variety of subunit vaccines in preclinical models. We previously showed that escalating-dosing immunization (EDI), where a vaccine is dosed every other day in an increasing pattern over 2 weeks dramatically amplifies humoral immune responses.
-
Jul 5, 2023 | 00642-6&sz=64)
cell.com | Byrd T.T |Duncan M. Morgan |Laura Maiorino |Alexander Hostetler
Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
